SoftWave Tissue Regeneration Technologies announced its DermaGold,® an advanced wound care technology, has received an Innovative Technology contract from Vizient, Inc. the nation’s largest member-driven health care performance improvement company. The contract was awarded based on the recommendation of SoftWave’s DermaGold® by hospital experts who serve on one of Vizient’s member-led councils, and it signifies...Read More
Amazon Healthcare veteran Chris Holt brings experience and a bold vision to lead SoftWave TRT's market expansion and product innovation efforts Kennesaw, GA, May, 4– In March 2022, Chris Holt joined SoftWave TRT as a strategic advisor and co-CEO, bolstering the company's growth and clinical effectiveness across various healthcare sectors.Read More
SoftWave officially has been granted 4 new patents as of July 19, 200. They include e U.S. Patient No. 11,389,373 B2 for Acoustic shock wave therapeutic methods to prevent or treat opioid addiction, U.S. Patient No. 11,389,370 B2 for Treatments for blood sugar levels and muscle tissue optimization, U.S. Patient No. 11,389,371 B2 and U.S....Read More
Exclusive agreement to supply Cynosure LLC, a global leader in medical aesthetics, with its patented extracorporeal shock wave devices for distribution in the United States and Canada primarily to medical doctors and their practices.Read More
SoftWave® Tissue Regeneration Technologies, a disruptive bio-medical device company, announces the beginning of a trial for “Extracorporeal Shock Wave Therapy in Acute Traumatic Complete and Incomplete Cross – Sectional Lesions.” The trial will be sponsored by the Austrian Workers’ Compensation Board (AUVA). It will be conducted in 13 hospitals in Austria and one in Germany,...Read More
ATLANTA, May 19, 2021 (Newswire) – SoftWave Tissue Regeneration Technologies patented extracorporeal shock wave device called the OrthGold 100® was cleared by the FDA on May 4, 2021, for the indications of a temporary increase in local blood circulation, relief of minor aches and pains, and activation of connective tissue. (FDA 510(k) letter-number K210451.) According to...Read More
